Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Por um escritor misterioso
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
ex99-01_img005.jpg
Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB
FDA Approves sNDA for Rexulti for Adolescents With Schizophrenia
Investigation Questions Drug's Approval for Agitation in AD
Patient Group Input Submissions: Brexpiprazole (Rexulti) - NCBI Bookshelf
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
What you need to know about Rexulti (Brexpiprazole)
Rexulti Full Prescribing Information, Dosage & Side Effects
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
ex9902003.jpg
Rexulti Full Prescribing Information, Dosage & Side Effects
de
por adulto (o preço varia de acordo com o tamanho do grupo)
:max_bytes(150000):strip_icc()/Thales_of_Miletus._Line_engraving_by_Blanchard._Wellcome_V0005771-8c2d770336b9453b8171233df5bf14c4.jpg)